Dr. Thomas J. Hudson is President and Scientific Director of the Ontario Institute for Cancer Research (OICR), an Institute created to support multidisciplinary teams needed to effectively translate research discoveries into interventions for better prevention, detection, diagnosis and treatment of cancer. Since its inception, OICR has launched several large-scale programs including the Ontario Health Study, the One Millimetre Cancer Challenge, the Cancer Stem Cell Program, the Pancreatic Cancer Genome Project (which is part of the International Cancer Genome Consortium), the Terry Fox Research Institute/OICR Selective Therapies Program and High Impact Clinical Trials.
Dr. Hudson is internationally renowned for his work in genomics and human genome variation. Past positions include leadership roles as Director of the McGill University and Genome Quebec Innovation Centre and Assistant-Director of the Whitehead/MIT Center for Genome Research, where he led a team that generated physical and gene maps of the human and mouse genomes. Dr. Hudson has been a founding member of the International Haplotype Map Consortium, the Public Population Project in Genomics (P3G) and the International Cancer Genome Consortium. Dr. Hudson's laboratory at OICR is involved in the study of genome variation that affects cancer predisposition, progression, and response to therapy. His main project focuses on the genetic architecture of loci associated with risk to colorectal cancer.
In 2007, Dr. Hudson was appointed to the rank of Professor in the Department of Molecular Genetics at the University of Toronto. Dr. Hudson is a fellow of the Royal Society of Canada. He is editor-in-chief of the journal Human Genetics. Dr. Hudson has co-authored over 200 peer-reviewed scientific publications.